Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15015776 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14CA12KMT2ATP53 | |
| SCHEMBL561667 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2CA14CA12KMT2ACA7 | |
| SCHEMBL5512536 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2CA14CA12KMT2ACA7 | |
| SCHEMBL5328441 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14CA12KMT2ATP53 | |
| SCHEMBL5328444 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14CA12KMT2ATP53 | |
| SCHEMBL16438180 | 0.81 | TP53 (0.50) | TP53SLC7A5FPR1FPR2ALDH1A1 | |
| SCHEMBL659817 | 0.81 | TP53 (0.50) | TP53SLC7A5FPR1FPR2ALDH1A1 | |
| SCHEMBL15015930 | 0.78 | TSHR (0.40) | SMN1; SMN2CA14CA12TP53SLC7A5 | |
| SCHEMBL17124707 | 0.78 | TSHR (0.40) | SMN1; SMN2CA14CA12TP53SLC7A5 | |
| SCHEMBL14571319 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14CA12KMT2ACA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148524-A1 | TACKIFIER COMPOUNDS AND METHODS OF USING THE SAME | IOWA STATE UNIV RESEACH FOUNDATION INC (US) | 2018-05-31 | — | — | US | disclosed |
| US-9920145-B2 | Tackifier compounds and methods of using the same | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170226243-A1 | TACKIFIER COMPOUNDS AND METHODS OF USING THE SAME | UNIV IOWA STATE RES FOUND INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-9688794-B2 | Tackifier compounds and methods of using the same | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150274861-A1 | TACKIFIER COMPOUNDS AND METHODS OF USING THE SAME | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274861-A1 | TACKIFIER COMPOUNDS AND METHODS OF USING THE SAME | ORC3, OR10J3, NR2C2 | SMN1; SMN2 2964/4885CA14 1164/4885CA12 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.